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ABSTRACT
Cisplatin is an extremely effective cancer chemotherapeutic agent, but its use is often
accompanied by toxicity. Second generation drugs such as carboplatin are becoming more widely
used because of reduced toxicity. Since biotransformation products have been implicated in the
toxic responses, we have begun to investigate the reactions of cisplatin and carboplatin with
potential biological ligands. Reaction products were charac.tedzed using HPLC with inductively
NMR and fast atom coupled plasma- mass spectrometry (HPLC-ICP-MS), H and C
bombardment mass spectrometry (FA_B-MS). Three Pt-creat_inine complexes,
2/ 2+ cs-[Pt(NH3);Cl(Creat)] cts-[Pt(NH3)(H20)(Creat)] and cts-Pt(NH3)(Creat)2] were synthesized
and the platinum was shown to coordinate to the ring nitrogen, N(3). Human urine samples from
patients on cisplatin chemotherapy were shown to contain cisplatin, its hydrolysis product and
biotransformation products containing Pt-creatinine, Pt-urea and Pt-udc acid complexes. Urine
from carboplatin patients shows fewer biotransformation products. Studies with control and
diabetic (protected against cisplatin toxicity) rats showed systematic differences in the
biotransformation products formed on administration of cisplatin.
INTRODUCTION
Cisplatin, cis-diamminedichloroplatinum(ll), is one of the most widely used and most successful
cancer chemotherapeutic agents (1,2). Cisplatin is most effective in the treatment of metastatic
testicular tumors, but has been used either alone or in combination protocols for the treatment of a
number of other types of tumors (3). Them is strong evidence to suggest that DNA represents the
principal target for cisplatin in the cell (2), however, the interaction of cisplatin with other biological
molecules has been less well studied. The clinical application of cisplatin is accompanied by
significant toxicity, of which nephrotoxicity is dose limiting (4). Although the mechanism of
nephrotoxicity is still unknown, the biotransformation products of cisplatin are believed to play a
role (5). A number of "second generation" platinum complexes, such as carboplatin, have been
developed in an attempt to overcome the toxicity problems experienced by cisplatin patients (see
reference 6 for a review). The observed reduction of toxicity with carboplatin, which may be a
function of its lower rate and degree of biotransformation, has resulted in its increasing use in
clinical treatment protocols (7).
Previous studies have identified Pt-methionine complexes in rat plasma after cisplatin treatment
(8). Also, them is evidence suggesting the formation of Pt complexes with cysteine and
glutathione in kidney cytosol and urine of rats treated with cisplatin (9). The reactions of cisplatin
with S-containing compounds such as methionine, cysteine and glutathione, have been
extensively investigated using HPLC, mass spectrometry (MS) and NMR (10-13). However, few
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studies with other biological ligands such as creatinine have been reported. Creatinine is an end
product of creatine metabolism, whose concentration in serum and urine is used as an indicator of
renal function. Elevated blood levels of creatinine are indicative of kidney damage (14). Geraldes
et al. found that several dimeric Pt-creatinine complexes formed in the 1:1 reaction of cis-
diammine-diaquaplatinum(ll) with creatinine (15). Various products were also obtained when
PtX
2 (where X is CI (16, 17) or NO2 (17, 18)) reacted with creatinine.
Previously we have used HPLC interfaced with inductively coupled plasma mass spectrometry
(HPLC-ICP-MS) to investigate various biotransformation products of gold antiarthritis drugs (19)
and possible products of cisplatin reactions with sulfur ligands such as cysteine and methionine
(20). Here we describe the reactions of cisplatin with nitrogenous ligands such as creatinine, urea
and uric acid. Further characterization of the creatinine containing products has been obtained
using fast atom bombardment- mass spectrometry, H and C NMR spectrometry. Urine
specimens from human patients undergoing cisplatin or carboplatin chemotherapy have been
examined and some biotransformation products identified. Rats have been treated with
streptozotocin (STZ) to make them diabetic and apparently create some level of protection from
the nephrotoxicity associated with administration of high doses of cisplatin (21). Rat urine
specimens have been examined and appear to show some systematic differences in
biotransformation products. We report those details here.
MATERIALS AND METHODS
Chemicals. Cisplatin was purchased from Johnson Matthey (Ward Hill, MA). Creatinine (Sigma),
urea (Fisher Scientific, >99%) and uric acid (Aldrich, >99%) were used upon receipt without further
purification. All other chemicals were obtained from various commercial sources and used as
received. Water used in the preparation of mobile phase and other solutions was purified (18 M)
with a Barnstead Nanopure system (Milford, MA) equipped with a 0.2 im filter.
HPLC. Two HPLC systems were used during the course of this work, a Waters (Milford, MA)
model 600 E Multisolvent Delivery System or a model 510 isocratic system. Samples were
injected using Rheodyne (Cotati, CA) 7125 injectors equipped with 20 or 50 IL sample loops.
Separations were performed on a Rainin (Woburn, MA) Microsorb-MV Cs column with 250 mm x
4.6 mm I.D. and 5 im particle size. A Hamilton (Reno, Nevada) PRP-1 column with 150 mm x 4.1
mm I.D. and 5 im particle size was used to confirm the identity of several sample peaks with
known materials. An AIItech (Deerfield, IL) AdsorbsphereC cartridge guard column (10 mm x4.6
mm I.D., 5 im particle size) or a Rainin Dynamax guard column (45 mm x 4.6 mm I.D., 5
particle size) were also used. The two mobile phase systems used throughout the experiments
were similar to that described by Zhao et al.(20). One consisted of 0.1% tdfluoroacetic acid (TFA),
1.0 mM 1-heptanesulfonate and 15% methanol. A second mobile phase used 0.1% TFA, 7.0 mM
1-heptanesulfonate and 5% methanol. The pH for each was adjusted to 2.6-2.7 using NaOH
solution. Prior to use, the mobile phase was filtered through a 0.45 im Nylon-66 membrane and
ultrasonicated to eliminate dissolved gasses. All separations were performed in an isocratic mode
with a flow rate of 1.0 ml/min. Chromatographic conditions were altered for some experiments to
facilitate the observation of species other than the hydrolysis products (i.e. products of the
reactions with creatinine or urea). Retention characteristics of aquated products were vetted for
each set of chromatographic conditions including the addition of AgNOz to change the relative
amounts of the hydrolysis products.
ICP-MS. Eluent from the HPLC column was analyzed on-line with a Sciex Elan 250 inductively
coupled plasma mass spectrometer (Toronto, Ontario). The column was coupled to the
instrument via PTFE capillary tubing (96 cm x 0.1 mm I.D.). The tubing has a volume of
approximately 0.08 iL/cm and has a minimal effect on extra-column peak broadening (22). The
instrument was operated in selected ion detection mode and platinum, m/z 195, was monitored.
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Typical operating parameters for the ICP-MS were: RF power, 1.25-1.4 kW; nebulizer argon flow
rate, 0.4 L/min; auxiliary argon flow rate, 1.1 L/min; coolant flow rate, 14 L/rain; spray chamber, 2-
5C.
NMR Spectra. The H (250.15 MHz) and C (62.90 MHz) NMR spectra were recorded on a
Bn3ker AC 250 spectrometer. H spectra were referenced to 2,2-dimethylsilapentanesulfonate
(DSS) as an internal standard. The free creatinine sample was prepared by dissolving creatinine
(0.0086 mmol) in 1 mL of H20. The 1:1 reaction mixture of cisplatin and creatinine was prepared
by incubating 0.0086 mmol cisplatin with 0.0086 mmol creatinine in 1 mL of H20 for 3 h at 47C.
The 1:2 reaction mixture was prepared by incubating 0.0086 mmol cisplatin with 0.0174 mmol
creatinine in 1 ml of HO for 24 h at 47C. Phosphate buffer was not used in these experiments
due to the concern that cisplatin may react with phosphate to form phosphato complexes (23, 24).
D20 (20%) was added to all samples to ensure a deuterium lock and continuous wave decoupling
was employed to suppress the HO resonance.
Composite pulse decoupling (VVALTZ-16) C spectra were recorded with respect to
tetramethylammonium chloride (TMA) as an external standard. The chemical shift of TMA in D20
was measured relative to tetramethylsilane in CDCI using a concentric arrangement. Data
acquisition was for 20% DO solutions of free creatinine or the 1:2 Pt-creatinine complex.
FAB-MS Spectra. These spectra were obtained on a VG 30-250 mass spectrometer.
3-Nitrobenzyl alcohol was used as matdx and the spectra were detected using positive ion
detection mode. The 1:1 reaction products of cisplatin and creatinine were formed by incubating
0.083 mmol cisplatin and 0.083 mmol creatinine in 10 mL of water for 3 h at 47C. The reaction
solution was concentrated by lyophilization and then redissolving in a small volume of water
(several IL). The 1:2 reaction products were formed by incubating 0.083 mmol cisplatin with 0.166
mmol creatinine in 2.4 mL of aqueous solution for 24 h at 47C. After incubation, 0.31 mmol
LiSO was added to the solution and then ethanol was introduced dropwise until a white
precipitate formed. The precipitate was collected by vacuum filtration, washed with methanol and
analyzed by mixing the solid with the matrix at the probe tip.
Preparation of Reaction Solutions for HPLC Analysis. The cisplatin hydrolysis products were
prepared by incubating 0.001 mmol cisplatin in 5 mL of saline solution (0.9% NaCI) at 37C for 12
hours. Diamminediaquaplatinum(ll) was prepared by incubating 0.005 mmol cisplatin with a
stoichiometdc amount of silver nitrate in 5 mL water in absence of light for 12 h at room
temperature. The solution was then filtered (0.45 im, Polysulfone) to remove the AgCI precipitate.
The preparation of the 1:1 reaction mixture of cisplatin and creatinine is described above. The
reaction products of cisplatin and urea were formed by incubating cisplatin (0.002 mmol) with urea
(3.33 mmol) in 10 mL of water for 5 h at 37C. The reaction of cisplatin and uric acid was studied
by incubating cisplatin (0.002 mmol) with uric acid (0.018 mmol) in 10 mL of water for 6 h at 37C.
The solutions of platinum complexes were diluted to the desired concentration with mobile phase
immediately prior to analysis.
Urine Samples. In some experiments, male Sprague-Dawley rats were injected with cisplatin (5
mg/kg, intravenous) and immediately placed in metabolism cages arranged for collection of feces-
free udne. After collecting for 2 hours, the urine was immediately analyzed. Urine from STZ-
diabetic as well as normal rats was collected (25). Human urine specimens were collected from
patients receiving cisplatin or carboplatin chemotherapy (26). The clinical urine samples were
either analyzed immediately after collection or divided into 1.5 mL aliquots, flash frozen with liquid
nitrogen and stored in the absence of light at-20C. Specimens were thawed rapidly using a
method described by Kinoshita (27). All urine samples were filtered through 0.45 im polysulfone
filters and diluted with mobile phase prior to analysis.
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RESULTS
Reactions of cisplatin with creatinine. One goal of these experiments was to develop methods
to identify biotransformation products of cisplatin, since it is believed that these products may
contribute to the toxicity observed with the drug (5). In aqueous solution, the two labile chloride
ligands in cisplatin can be displaced by water or hydroxyl ion. Figure la shows the HPLC-ICP-MS
separation of cisplatin (C) and its hydrolysis products. Both the monoaqua (H) and diaqua (H2)
hydrolysis products are formed after incubation in saline solution for 12 h at 37C. These
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Figure 1 (a) HPLC-ICP-MS separation of cisplatin (C), mono-aqua (H) and diaqua hydrolysis
(H2) products. Mobile phase conditions: 0.1% trifluoroacetic acid (TFA), 1 mM 1-
heptanesulfonate, 15% methanol, pH 2.6-2.7. Column" Rainin Microsorb-MV Cls. The ICP-MS
was set to monitor Pt at m/z 195. (b) HPLC separation of 1"1 reaction mixture of cisplatin
and creatinine. Three Pt-creatinine complexes (peak R1,R2 and R) are formed. LC
conditions as in (a). The insert shows the structural formula of creatinine.
hydrolysis products were identified by adding AgNOz to cisplatin in aqueous solution to drive the
ligand exchange equilibrium toward the formation of the diaqua species. A subsequent
chromatogram of this solution thus permitted the identification of the diaqua hydrolysis product.
Cisplatin may undergo reactions with various biological nucleophiles resulting in biotransformation
products which may have activity and toxicity different from that of the parent drug. Creatinine is
an end product of creatine metabolism, whose concentration in serum and urine is used as an
indicator of renal function. Elevated blood levels of creatinine are indicative of kidney damage
(14). The presence of several electron donor groups on creatinine provides multiple ligation sites
for platinum. HPLC separation of the 1:1 reaction mixture of cisplatin and creatinine is shown in
Figure lb. Cisplatin (C), the monoaqua hydrolysis product (H) and three Pt-creatinine complexes
(peak R,R2 and R) are observed. Peak R is the dominant component. Under these reaction
conditions little, if any of the diaqua hydrolysis product is produced.
To further characterize the three Pt-creatinine complexes, H NMR was used to monitor the
reaction mixtures obtained at different molar ratios of cisplatin and creatinine. Figure 2 shows the
spectra of free creatinine and the 1"1 and 1:2 reaction solutions of cisplatin and creatinine. The
chemical shifts of the CH3 and CH2 protons in free creatinine are 3.03 and 4.04 ppm respectively
(Figure 2a). Two new resonances of the CH protons are observed shifted down field by 0.05 and
0.08 ppm upon complexation with platinum, however only one new signal (111) from CH2 is
observed. This may be due to peak overlapping. In the 1 "1 reaction solution (Figure 2b), signal is
the major resonance of CH3 protons. In Figure 2c, signal II becomes the dominant resonance
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when cisplatin reacts with creatinine at a 1:2 molar
ratio. This change suggests that signal results from a
1:1 platinum-creatinine complex and signal II from a
1:2 platinum-creatinine complex.
The mass spectrum of the 1:1 reaction mixture of
cisplatin and creatinine is shown in Figure 3. The
molecular ions of the 1"1 Pt-creatinine complex,
cis-[Pt(NH)2Cl(Creat)]*, and the 1:2 Pt-creatinine
complex, cis-[Pt(NHz)2(Creat)2+H]+’ are observed
(peaks at 376-380 and 453-457 respectively). Here, the
1:2 complex loses H, forming the [M-H] ion. The peak
intensities in m/z 376-380 and 453-457 regions are
compared with the theoretical isotopic abundance
calculated from molecular formulas (Table I). It can be
seen that the intensity distributions in both regions
match their corresponding theoretical abundance. In
addition, the peaks at m/z 359-363 correspond to the
loss of one NH3 from the cis-[Pt(NH3)2Cl(Creat)]* ion
and signals at m/z 436-438 and 419-421 result from
the cis-Pt(NHz)2(Creat)2-H] ion losing one and two
NHz respectively. These observations confirm that the
peaks at m/z 376-380 are the molecular ions of the 1:1
Pt-creatinine complex with one platinum and one
chlodde present in its structure. The group of peaks at
Figure 2 H NMR spectra of (a) free m/z 453-457 correspond to the 1:2 complex formed by
creatinine (b) 1:1 and (c) 1:2 displacing the two chloride ligands of cisplatin with
reaction mixture of cisplatin and creatinine.
creatinine.
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Figure 3 FAB-mass spectrum of the 1:1 reaction mixture of cisplatin and creatinine.
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Using this mass spectrum, we conclude that peak 1 in Figure la is the 1:1 Pt-creatinine complex:
cis-[Pt(NH3)2Cl(Creat)]/. To identify the other two Pt-creatinine complexes, The 1:2 Pt-creatinine
complex was synthesized and isolated from the reaction solution by sulfate precipitation. The
chromatogram of this complex shows a dominant peak R3, with a small amount of the 1:1 complex
(peak R) present as an impurity. The mass spectrum of this solid product (Figure 4) shows a
molecular ion cluster with the most intense peak at m/z 552, which corresponds to cis-
[Pt(NH3)2(Creat)2SO+H]/. Thus peak R3 in Figure l a is identified as the 1:2 Pt-creatinine
complex, cis-[Pt(NH3)2(Creat)2]2/. When this 1:2 complex was incubated in water for 6 h, peak R3
remained unchanged, peak R decreased and peak R2 appeared at ca. 940s. Thus peak R2 is
likely to be the 1 "1 complex, cis-[Pt(NH3)2(H20)(Creat)]2/, formed from cis-[Pt(NH3)2Cl(Creat)] via
exchange of chloride with water.
Table Masses and relative intensities of cis- [Pt(NH)2Cl(Creat)]
/
and cis-[Pt(NH3)z(Creat)z]
2+
(a) cis-[Pt(NH3)2Cl(Creat) m/z 376-380
Mass (m/z) Relative intensity (%) Relative abundance (%)
(Measured) (Calculated)
376 91.3 86.8
377 100.0 94.3
378 99.9 100.0
379 39.5 34.9
380 43.3 42.3
(b) cis -[Pt(NH3)2(Creat)2- H]/, m/z 453-457
Mass (m/z) Relative intensity (%) Relative abundance (%)
(Measured) (Calculated)
453 92.7 86.9
454 100.0 100.0
455 77.9 78.8
456 9.4
457 21.6 19.8
* The signal of m/z 456 is not differentiated from base line.
To determine the Pt-coordination site on creatinine,C NMR spectra of free creatinine and the 1:2
Pt-creatinine complex were measured. The chemical shifts of the C0, C2, C4 and C5 of creatinine
are 30.36, 169.51, 189.09 and 56.60 ppm respectively. The assignments are based on previous
work (15, 28). The resonances of the 1:2 Pt-creatinine complex occur at 31.42, 164.36, 182.55 and
55.00 ppm respectively (29). The chemical shifts of C2 and C4 show large changes (5.15 and 6.54
ppm respectively), while signals from C, and Cs shift slightly (1.06 and 1.60 ppm respectively).
These data suggest that creatinine forms complexes with platinum through the cyclic nitrogen
N(3). This is consistent with the structure of cis -[Pt(Creat)212].3H;O determined by X-ray
crystallography (30).
Reactions of urea and uric acid with cisplatin. Based on their structures and relative
abundances in urine, urea and uric acid were incubated with cisplatin to determine whether new
platinum containing products formed. The reaction of cisplatin and urea produced three platinum
complexes (Figure 5a). The major product (ca. 675 s) is adjacent to the monoaqua hydrolysis
product and is not completely separated from it. In addition two minor products are observed at
ca. 810 and 910 s. An additional byproduct of cisplatin hydrolysis is also observed at ca. 240 s and
has not yet been identified. In this separation, a higher concentration of the ion pairing agent and a
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lower methanol concentration were employed to improve the resolution of overlapping peaks. The
diaqua hydrolysis product is retained by the column and is not observed under this
chromatographic condition.
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Figure 5 HPLC separation of the reaction mixture of cisplatin and (a) urea and (b) Uric
acid. The reaction of cisplatin and urea produced three Pt-urea complexes: the major
product (peak 1: ca. 675 s) and two minor components at ca. 810 (peak 2) and 910 s (peak
3). Incubation of cisplatin and uric acid also showed the formation of several new
species (peaks 1-6). Mobile phase condition: 0.1% TFA, 7 mM l-heptanesulfonate, 6%
methanol, pH 2.6-2.7. Column: Rainin Microsorb-MV Cle. The retention times for cisplattn
(C) and the monoaqua hydrolysis product (H) are indicated.
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The incubation of cisplatin and uric acid also resulted in the formation of several new platinum
species (Figure 5b). Again, although complete separation of all of the components is not attained,
qualitative identifications can be made. By changing the mobile phase conditions slightly (10%
methanol) and using on-line IJV detection, peak 4 has been determined to contain an additional
minor component not shown here. Further characterization of these products is in progress.
Identification of Biotransformation Products in Rat Urine. Rats treated with streptozotozin
(STZ) suffer pancreatic damage and develop a diabetic condition (31). Interestingly, these
animals, when compared to control rats, are resistant to the kidney damage which accompanies
high doses of cisplatin (32). The mechanism of the protection is not known. We examined urine
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Figure $ HPLC separation of urine from (a) control and (b) diabetic rat treated with
cisplatin. The major component is cisplatin. Several platinum species are observed. The
retention times of two species agree with that of the monoaqua hydrolysis product and the
1:1 Pt-creatinine complex, cis-[Pt(NHz)=Cl(Creat)]/. LC conditions as in Figure 1. Retention
times for cisplatin (C), the monoaqua hydrolysis product (H) and the 1:1 reaction product
of cisplatin and creatinine (R1) are indicated.
specimens from both diabetic and control rats injected with cisplatin (5 mg/kg). The HPLC-ICP-MS
chromatograms are shown in Figure 6. The major component is cisplatin, but several other
platinum containing species are observed as well. Two of the species show retention times
expected for the monoaqua hydrolysis product and the 1:1 Pt-creatinine complex,
cis-[Pt(NH3)2Cl(Creat)]/
The identity of the Pt-creatinine complex was confirmed in two ways. First, a similar quantity of the
synthetic complex was added to the rat urine specimen. The peak attributed to the complex grew
in size but did not change shape, indicating an exact equivalence in retention times between the
known complex and that in the rat urine specimen. Second, further evidence for the identity of the
1:1 Pt-creatinine complex in rat udne was provided by separating both the udne sample and the
1:1 reaction mixture of cisplatin and creatinine on a PRP-1 column. The stationary phase of the
PRP-1 column is a polystyrene-divinylbezene copolymer. The retention mechanism of the PRP-1
column is based on adsorption, which differs from the partition mechanism of a regular
column. Therefore any peak coelution may be tested by chromatographing each of the samples on
two different columns. Again, one of the platinum containing species in the rat urine elutes at the
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same retention time as this 1:1 complex, which implies that cis -[Pt(NH)Cl(Creat)] is present.
Figure 6a shows the chromatogram of urine from a control rat, whereas that in Figure 6b is from a
diabetic rat. In both cases the overall distribution of peaks is quite similar; however, there is an
additional peak in Figure 6b (ca. 500 s) which was also present in a urine specimen from a second
diabetic rat and missing from the urine specimens of four different control rats treated with
cisplatin. The identity of this peak is under study. We currently do not know whether this is a
"protective" species. It is clearly a minor component of the total platinum present in urine.
Cisplatin and Its Biotransformation Products in Human Urine. Having identified specific
biotransformation products in the urine of rats, we monitored urine samples from a number of
cancer patients to determine the platinum species present. Figure 7 shows the platinum species in
urine taken from a patient being treated with cisplatin for lung cancer. The peak for cisplatin
corresponds to the major component. There is a significant contribution from the monoaqua
hydrolysis product of the drug as well. More interestingly the second most abundant
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Figure 7 HPLC separation of udne sample from a lung
platinum-containing species is the
1:1 Pt-creatinine complex:
cis-[Pt(NH3)2Cl(Creat)]*. A peak
which is not completely separated
from the monoaqua hydrolysis
product at ca. 675 s has the same
retention time as a cisplatin-urea
reaction product and is presumed
to be that material. One peak at
at ca. 225 has the same retention
time as one of the uric acid-
cisplatin reaction products.
Another peak at 106 s is
unidentified. Under these
chromatographic conditions, the
diaqua hydrolysis product of
cisplatin elutes after 1800 s.
cancer patient. The patient was given 0.5L saline as We have now examined urine
hydration therapy (33), followed by a two hour infusion specimens from a number of
of cisplatin. LC conditions are as in Figure 5. Specific different patients, using samples
peaks are identified based on retention time. taken immediately after drug
infusion or three to four weeks
after the initial treatment. Figure
8a shows the HPLC separations of samples from four different patients. The dominant platinum
containing species in all cases has the retention time of cisplatin. All samples also contain species
with the retention times for the monoaqua hydrolysis product and the 1:1 cisplatin-creatinine
complex (R1). As with the rat samples, the identity of R was confirmed by the addition of the 1:1
reaction mixture to the udne specimen. The peak at approximately 800 s increased in height but
did not change in shape.
We have also analyzed the udne of patients approximately three weeks after one dose
(immediately prior to the next dose). In these patients, them is still a significant amount of
platinum present. Platinum levels immediately after treatment are typically in the 30-50 ppm
range, while after three weeks, levels are in the 50-100 ppb range. Figure 8b shows
chromatograms of several udne samples taken after three weeks. The upper and middle traces
are from one patient, but taken on two different dates. Both chromatograms show several
platinum peaks, indicating that significant biotransformation of the cisplatin has occurred during
the time following treatment. Many of the platinum species have the same retention times, but the
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quantitative distribution is not identical. After a three week pedod all three samples show little, if
any, of the native cisplatin, nor of the monoaqua hydrolysis product. The identities of the new
platinum species have not been determined.
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Figure 8 HPLC separation of urine from cisplatin patients. (a) Samples were taken
immediately after cisplatin infusion and (b) samples taken three weeks following treatment.
(C) indicates cisplatin, (H) the monoaqua hydrolysis product, (R1) the 1:1 reaction mixture
of cisplatin and cmatinine. Mobil phase: 0.1% TFA, 5 mM heptanesulfonate, 10% methanol,
pH 2.6-2.7. Column: Ranin Microsorb-MV-Ce.
Carboplatin in Human Urine. We have begun to use HPLC-ICP-MS to study carboplatin and its
biotransformation in patient samples. The HPLC separations of urine from three patients are
shown in Figure 9. Specimens analyzed in the left panel were taken immediately following the
carboplatin treatment. The right panel shows analyses of urine from the same patients three
weeks after treatment. In all three samples immediately after treatment, the main platinum
species present is carboplatin. In one of the patients, there is an additional platinum species
present, which is not retained by the column. A minor platinum peak is also present in all the
samples at approximately 375 s. None of these species correspond to those observed in the urine
of the cisplatin patients. In the urine samples collected three weeks after the dose, there is still
significant platinum present (150-275 ppb). By this point, significant biotransformation has
occurred. Interestingly, in one of the patients, Patient 5, there are platinum species present which
have the retention times for cisplatin and the monoaqua hydrolysis product. This result provides
evidence that carboplatin can be converted in vivo to cisplatin, followed by hydrolysis and
presumably other subsequent reactions characteristic of administered cisplatin.
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Figure 9 HPLC separations of udne from patients treated with carboplatin. Samples were
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Discussion
Clearly the biotransformation chemistry of cisplatin is extremely rich. Others have shown evidence
that cisplatin-glutathione products are formed in the body (9). By using HPLC analysis coupled
with ICP-MS to provide platinum specific detection, we have shown that a large number of
biotransformation products can be formed as a result of in vitro reactions with nitrogenous ligands
such as creatinine, urea and uric acid. Some of these reaction products are detectable in the
urine of patients undergoing cisplatin chemotherapy. Comparison of the chromatograms from
samples taken immediately after therapy with those taken weeks later indicates that significant
biotransformation continues to occur. In a single individual, the chromatograms taken at different
times are qualitatively similar, but there are quantitative differences. Comparison of samples from
different individuals reveals some qualitative differences as well.
Comparison of the samples from cisplatin and carboplatin patients illustrates significant
differences between the two drugs. The samples from carboplatin patients taken immediately
after treatment show fewer biotransformation products, with carboplatin itself being the principal
platinum species present. This observation is likely the result of the "relative stability" of the
leaving groups of the two compounds (6). Essentially all the Pt detectable by flow injection is
recovered on the chromatographic column. The pdmary metabolite identified in rat urine, a ring-
opened adduct of carboplatin-methionine (34) is not present in these patients. The cationic
methionine complex should elute after the carboplatin under these chromatographic conditions. In
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the weeks following treatment, at least one of the carboplatin patients appears to have
metabolized the compound into cisplatin, since the chromatogram shows peaks with the retention
times for both cisplatin and the monoaqua hydrolysis product (Figure 9b). This is a confirmation of
the suggestion that cisplatin is a metabolite of carboplatin (35).
Using HPLC coupled to the ICP-MS for platinum-specific detection will allow us to gain a great
deal more insight into the biotransformation chemistry of cisplatin and the next generation agents
such as carboplatin. Hopefully these insights will lead to better control of toxicity and higher
efficacy for platinum antineoplastic agents.
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